BRD4调控驱动去势抵抗性前列腺癌上皮间质转化的关键转录因子
本研究利用不同雄激素受体(AR)组成的前列腺癌细胞系系统调控BET家族蛋白(BRD2、BRD3、BRD4),发现仅BRD4调控SNAI1和SNAI2表达,下调这些EMT转录因子显著增加E-钙黏蛋白表达。TCGA数据分析显示仅BRD4与前列腺癌患者生存结局相关(414例生化复发、488例无进展生存)。BRD4选择性降解剂MZ1可消除TGFβ信号诱导的EMT(转录和形态学层面),提示BRD4选择性蛋白降解剂是治疗mCRPC的新靶点。
要点
- BRD4而非BRD2或BRD3调控EMT转录因子SNAI1和SNAI2。
- 仅BRD4表达与前列腺癌患者生存结局相关。
- BRD4选择性降解剂MZ1可消除TGFβ诱导的EMT。
核心结论
- BRD4调控驱动EMT的关键转录因子SNAI1和SNAI2,是治疗mCRPC的可成药新靶点。
- BRD4选择性蛋白降解剂有望成为治疗晚期前列腺癌化疗耐药的新一代方法。
研究设计与样本
- 利用不同AR组成的前列腺癌细胞系系统调控BET家族蛋白(BRD2、BRD3、BRD4)以确定影响EMT的BET蛋白。
- 使用TCGA数据库分析BET基因表达与EMT基因的相关性,并在414例患者中评估生化复发、488例患者中评估无进展生存。
主要发现
- 仅BRD4(而非BRD2或BRD3)调控SNAI1和SNAI2表达,下调这些EMT转录因子显著增加E-钙黏蛋白表达。
- BET基因中仅BRD4与前列腺癌患者生存结局相关。
- BRD4选择性降解剂MZ1可消除TGFβ信号诱导的EMT(转录和形态学层面)。
临床怎么用
- BRD4表达或可作为mCRPC预后相关标志物。
- BRD4选择性蛋白降解剂为治疗mCRPC提供潜在新策略。
局限性
- 研究主要基于细胞系和TCGA数据库分析,尚需体内实验和临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen deprivation therapies for the hormone-dependent stages of prostate cancer have become so effective that new forms of chemoresistant tumors are emerging in clinical practice, and require new targeted therapies in the metastatic setting. Yet there are important gaps in our understanding of the relevant transcriptional networks driving this process. Progression from localized to metastatic castration resistant prostate cancer (mCRPC) occurs as a result of accumulated resistance mechanisms that develop upon sustained androgen receptor (AR) suppression. Critical to this progression is the plastic nature by which prostate tumor cells transition from epithelial to mesenchymal states (EMT). METHODS: Here, using prostate cancer cell lines with different AR composition, we systematically manipulated somatic proteins of the Bromodomain and ExtraTerminal (BET) family (BRD2, BRD3, and BRD4) to determine which BET proteins influence EMT. We used the TCGA repository to correlate the expression of individual BET genes with key EMT genes and determined biochemical recurrence in 414 patients and progression free survival in 488 patients. RESULTS: We found that only BRD4-and not BRD2 or BRD3-regulates the expression of SNAI1 and SNAI2, and that the downregulation of these EMT transcription factors significantly increases E-cadherin expression. Furthermore, of the BET genes, only BRD4 correlates with survival outcomes in prostate cancer patients. Moreover, selective degradation of BRD4 protein with MZ1 ablates EMT (transcriptionally and morphologically) induced by TGFß signaling. CONCLUSIONS: Many relapsed/refractory tumors share a neuroendocrine transcriptional signature that had been relatively rare until highly successful antiandrogen drugs like abiraterone and enzalutamide came into widespread use. New therapeutic targets must therefore be developed. Our results identify key EMT genes regulated by BRD4, and offers a novel druggable target to treat mCRPC. BRD4-selective protein degraders offer a promising next generation approach to treat the emerging forms of chemoresistance in advanced prostate cancer.
引用
- Shafran JS, Jafari N, Casey AN, et al. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32690869. doi:10.1038/s41391-020-0246-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。